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Background: Fifth metatarsal (MT-V) stress fractures often exhibit delayed union and are high-risk fractures for non-
union. Surgical treatment, currently considered as the gold standard, does not give optimal results, with a mean
time to fracture union of 12-18 weeks. In recent studies, the use of bone marrow cells has been introduced to
accelerate healing of fractures with union problems. The aim of this randomized trial is to determine if operative
treatment of MT-V stress fractures with use of concentrated blood and bone marrow aspirate (cB + cBMA) is more
effective than surgery alone. We hypothesize that using cB + cBMA in the operative treatment of MT-V stress
fractures will lead to an earlier fracture union.
Methods/Design: A prospective, double-blind, randomized controlled trial (RCT) will be conducted in an academic
medical center in the Netherlands. Ethics approval is received. 50 patients will be randomized to either operative
treatment with cB + cBMA, harvested from the iliac crest, or operative treatment without cB + cBMA but with a
sham-treatment of the iliac crest. The fracture fixation is the same in both groups, as is the post-operative care..
Follow up will be one year. The primary outcome measure is time to union in weeks on X-ray. Secondary outcome
measures are time to resumption of work and sports, functional outcomes (SF-36, FAOS, FAAM), complication rate,
composition of osteoprogenitors in cB + cBMA and cost-effectiveness. Furthermore, a bone biopsy is taken from
every stress fracture and analysed histologically to determine the stage of the stress fracture. The difference in
primary endpoint between the two groups is analysed using student’s t-test or equivalent.
Discussion: This trial will likely provide level-I evidence on the effectiveness of cB + cBMA in the operative
treatment of MT-V stress fractures.
Trial registration: Netherlands Trial Register (reg.nr NTR4377)
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Marines, soldiers and athletes are prone to fractures due
to extensive and repeated stress on (usually weight bear-
ing) bones [1–4]. These stress fractures develop over
time and are therefore different than the more com-
monly accounted traumatic fractures. The damage
caused by repeated forces on the bone outruns the nat-
ural remodeling process in loaded bones, resulting in a
weak spot or ‘stress reaction’ and eventually a stress frac-
ture [5–7]. Due to the increasing sports participation in
the general population and awareness of their existence,
these types of fractures are more frequently diagnosed.
Of all stress fractures of the lower leg, the stress fracture
of the fifth metatarsal has one of the highest incidences,
namely up to 25 % [8]. This issue is amplified in the pa-
tients that depend on perfect physical condition like pro-
fessional athletes. In a recent review of the literature, it
is described that operative treatment of fifth metatarsal
stress fractures results in smaller number of delayed
unions or non-unions, compared to conservative treat-
ment [9]. Still, the time to return to activity varies from
12 to 18 weeks [9–12].
Compared to a normal, traumatic fracture, stress frac-
tures do not seem to heal via callus formation, but ra-
ther by primary bone healing with remodeling across the
fracture line [7, 13, 14]. This process is slower with a
higher propensity to fail, resulting in a complete fracture
and refractory healing, similar to non-union [7, 14]. In
traumatic fractures healing starts with formation of
hematoma and therewith release of inflammatory cells.
The next phase is recruitment of mesenchymal cells that
differentiate into osteoblasts resulting in primary bone
formation with callus production followed by secondary
bone formation, with bone remodeling. In stress frac-
tures, healing starts with the remodeling phase. Via early
woven bone formation, callus is only formed along the
exit point of the fracture towards the medullary cavity
[15, 16].
Thus one of the major factors in bone repair seems to
be an inflammatory response with the activation of
Bone Marrow Stem Cells (BMSCs), which appears to be
the initiating step in the cascade of bone repair. BMSCs
give rise to the cells that form mesenchymal tissues like
bone and cartilage [17, 18]. The exact role of BMSCs
(available in cB + cBMA) in bone formation needs fur-
ther clarification, but previous studies with BMSCs
have provided evidence for new strategies of bone regu-
lation [22, 24, 19], especially in delayed- and non-union
fractures [20–26]. To our knowledge, there are no stud-
ies available for the role of cB + cBMA in stress frac-
tures. In this study, the effect of adding cB + cBMA to
operative treatment of MT-V stress fractures on the
time to union will be assessed and compared to opera-
tive treatment alone. We hypothesize that surgery withadding cB + cBMA of MT-V stress fractures results in
faster union times than surgery alone.
Methods/Design
Study design and informed consent
This study is a double-blind, randomized, placebo
controlled, multicenter trial, which is conducted in ac-
cordance with the Declaration of Helsinki [27]. The meth-
odology will follow the Consolidation of Standards of
Reporting Trials (CONSORT) guidelines [28, 29]. Ap-
proval has been obtained from the local institutional re-
view board Medical Ethical Commitee of the Academic
Medical Center, Amsterdam (METC AMC, study refer-
ence number: NL44188.100.13 2013_182). Before study
entry, all patients have to give written informed consent
prior to participation.
Randomization
Patients will be allocated to the intervention or sham-
control group after signing an informed consent through
a block randomization in random permutated blocks of
4, 6 or 8 patients using “Castor edc” [30]. Randomization
will be performed online by the researcher, one day pre-
operatively. At the end of the inclusion period there will
be an equal number of patients in each randomization
arm. Patients and X-ray assessors will be blinded to the
allocation of treatment during the complete study. It is
strictly forbidden for the blinded evaluator to discuss pa-
tient treatment with any study personnel. It is also
strictly forbidden for study personnel to discuss treat-
ment allocation with the patient. The key to the secured
allocation data will not be broken until all patients have
completed the study unless it is necessary for patient
safety. This key is with an independent doctor. Patient
data will be stored on hospitals’ server and only the re-
searcher can see this data files which is stored independ-
ent of allocation data.
Inclusion criteria
Patients will be considered to be included in this trial if
they fulfill all of the following criteria:




Subjects will be excluded from this trial if they meet any
of the following criteria:
 Expected non-compliance; patients who are unable
to fill out questionnaires
 Cavovarus deformity of the foot as measured on the
Salzmann view
 X ray of MT-V stress fracture
a b
Fig. 1 X-ray of MT-V stress fracture. a. AP view b. Oblique view. Stress fracture of the MT-V, located in the metaphyseal-diaphyseal junction also
called zone 2; or just distally from the intrametatarsal joint (MT-IV/MT-V) in the proximal diaphysis also called zone 3 [45], with sclerosis seen on
both fracture sides
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 Suffering from auto-immune disease
 Receiving biologicals, prednisolone or some kind of
chemotherapy within the previous year
 Concomitant painful or disabling disease of the
lower limb
 No informed consent
 Females being pregnant or nursing
 Known active malignancy
 Previous surgery for the present MT-V stress
fractureFig. 2 Inserting bone marrow aspirate into the device. Insert the
bone marrow aspirate into the Marrow Stim device, before putting it
in the centrifugeDevice description
The bone marrow required for the cB + cBMA treatment
will be harvested from patient’s own iliac crest through
needle aspiration. Two 30 cc syringes will be filled with
bone marrow. Utilizing the MarrowStim Concentration
System® (Biomet Biologics: Fig. 2) the bone marrow as-
pirate will be processed in a centrifuge (together with a
counterbalance, 3200 rpm for 15 min); the poor cell
plasma will be separated from the nucleated cell concen-
trate and the cBMA is realized (Fig. 3). No bone marrow
will be collected from the patients within the control
group; only a sham procedure will be performed bycreating a similar skin incision on the same location on
the iliac crest, to maintain patients’ blinding.
Standard treatment and investigational treatment
Experienced foot and/or ankle or trauma orthopaedic
surgeons will perform the surgeries of both groups,
Fig. 3 Bone Marrow Aspirate after centrifuging. Bone marrow
aspirate after centrifuging (cBMA) with: upper layer = cell poor
plasma; middle layer = nucleated cell concentrate; lowest layer = red
blood cells
Weel et al. BMC Musculoskeletal Disorders  (2015) 16:211 Page 4 of 8within 2 weeks after inclusion. In brief, the proximal
fifth metatarsal stress fracture will be approached and a
decortication along the fracture lines will be performed.
Part of this material will serve as a bone biopsy and is
send for histological examination. The stress fracture
will be internally fixated, with use of a cannulated intra-
medullary compression screw. The remaining material
from the decortication will be used as an internal bone
graft. The patients in the intervention group only will re-
ceive the cBMA mixed with 2 ml untreated autologous
peripheral blood (cB + cBMA), together with the internal
bone graft and serving as a natural scaffold; it will be
put into and around the fracture. Of the 6 ml cB +
cBMA obtained, 4 ml will be added to the fracture site
the other 2 ml is used for analysis.
Both groups will receive a similar rehabilitation proto-
col for the first 8 weeks after operation; first two weeks
in a non weight bearing-cast, then 2 weeks in a weight
bearing cast or walker allowed to have partial weight
bearing, thereafter 4 weeks in a weight bearing cast or
walker without restrictions.Outcome measures
The primary endpoint is the time to radiographic union
in weeks.
The secondary endpoints are: time to clinical union,
time to return to work and/or sport (in weeks), union
rate at each time point (in %), patient function and satis-
faction (SF-36, FAOS, FAAM), complication rate and
cost-effectiveness (SF-HLQ), compared between inter-
vention and control group.
During the operation a bone biopsy is taken. This will
be histologically analyzed. From the obtained cBMA a
2 ml sample will be analyzed (flow cytometry and amultiplex assay for detecting CD 31, CD 34, CD 45, CD
90, CD 105, CD 166 amounts, CFU-F assay and mRNA
analysis).
Objectives and hypothesis
The main objective is to determine the effect of cB +
cBMA on healing of surgically treated fifth metatarsal
stress fractures. We hypothesize that intramedullairy
screw fixation with cB + cBMA will generate a shorter
time to union. Furthermore we hypothesize that the
total costs are lower and that there will be a quicker re-
turn to sports or activities.
Definitions
Primary outcome
The primary outcome will be assessed on X-ray in differ-
ent directions; on AP view, lateral view and an oblique
view. The following will be scored by two single blinded
evaluators (skeletal radiologist and orthopaedic surgeon):
correct position osteosynthesis (yes/ no), fracture line
visible (yes/ no), % of fracture line visible, union (yes/ no).
The X-rays will be acquired every 2 weeks until the
14th week and, after that, only in the patients in which
radiological union has not yet occurred as deemed ne-
cessary by the treating physician.
Secondary outcomes
Clinical union will be measured during physical examin-
ation. Pain on axial compression force and pain on the
fracture site during palpation will be monitored through
a patient-based VAS score. When patients still report
significant pain, measured as a VAS > 3 on a Visual
Analogue Scale from 0 to 10 [31, 32], clinical union is
not yet achieved. Return to sports is defined as the time
(in weeks) to resumption of weight-bearing sports after
surgery and the level should be maintained for at least
30 days [33]; return to work is defined in the same way.
When returned to sport, but activity level decreases to
below the start level within 30 days after resumption,
then this will be deemed as a failed return to activity
and the date will not be counted. From the 6th till the
14th week, most unions are expected to occur. On each
of these biweekly time points a union rate will be
counted; number of unions at t = XXX divided by total
sample size (%).
The SF-36 is a patient-administered, generic health re-
lated quality of life instrument [34, 35]. The FAOS was
developed to assess the patients’ opinion about a variety
of foot and ankle-related problems [36]. The results can
be presented as an outcome profile. The FAAM is a 29-
item questionnaire. The FAAM consists of 2 subscales:
Activities of Daily Living and Sports [37].
Cost-effectiveness is analyzed using the The EuroQol
(EQ-5D) [38, 39] and the SF-36, FAOS, FAAM as
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calculated from the SF HLQ [40, 41] and the cost of the
investigated intervention. The questionnaire consists of
11 questions and provides information about labor
(missing) costs and additional paid working hours.
Results
Adverse events
Any (serious) adverse event during the trial period will
be recorded. Adverse events are defined as any undesir-
able experience occurring to a patient receiving an in-
vestigational medical device that does not necessarily
have to have a causal relationship with the device under
investigation, e.g. infection, numbness, or paraesthesia.
A serious adverse event (SAE) is any undesirable ex-
perience associated with the use of the investigational
treatment that results in death, is life threatening (at
the time of the event), requires hospitalization or pro-
longation of existing inpatients’ hospitalization, or re-
sults in persistent or clinically relevant disability or
incapacity. All SAEs will be reported to the local Med-
ical Ethics Committee within 15 days according to the
regulations.
Data collection
Data for this clinical trial will be collected and docu-
mented on specially designed subject Case Report Forms
(CRFs) provided digitally. Authorized study siteTable 1 Schedule for screening and follow-up of included participa









Obtain written informed consent X
Complete eligibility checklist X







- Operative form (surgical
information)
X
- cB + cBMA preparation and
administration
X
- Bone biopsy fracture site X
Lab assessments X
Questionnaires X X
Radiographic assessment X X X
Complication (form) X X X
Adverse events, withdrawals &
re-operation (form)
X X Xpersonnel will complete CRFs only. CRFs will be
reviewed and signed by the Investigator or his/her desig-
nees. Since there is a potential for errors, inaccuracies,
and misinterpretation in transcribing data onto the
CRFs, the following documents are available at all times
for inspection and comparison to the CRFs by the study
monitor where appropriate: data query forms, originals
and certified copies of all relevant records and reports,
copies of test results. On CRFs and patients’ cB + cBMA
samples, patients will not be identified by their names
but by an anonymized code. The subject identification
code list will be safeguarded by the investigator only.
Data acquisition and follow-up
Participating patients will be assessed at the following
time points (Table 1):
– before inclusion: information letter, complete
reliability checklist
– preoperatively (after an enrollment period of two
weeks): informed consent, complete reliability
checklist, baseline characteristics (age, gender,
weight, height, affected side, duration of symptoms,
smoking status, AAS before symptoms and at
preoperative assessment, past medical history,
medication used), type of sport and profession, local
physical examination with VAS, laboratory
assessment (Hemoglobin levels, leucocytes, sodium,nts
Follow-Up Visit Until Union (biweekly)
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36, EQ-5D, SF HLQ, X-ray (AP oblique and lateral);
– intraoperative: cB + cBMA preparation and
administration, bone biopsy of the fracture site, right
after internal fixation an X ray (AP, oblique and
lateral) and an operative form (surgical information)
with complications and (S)AEs if applicable;
– biweekly 2-14 weeks postoperatively: wound
inspection, local physical examination with VAS,
FAOS, FAAM, SF-36, EQ-5D, TiC, X-ray (best view
for analyzing the fracture), resumption of sports and
work, complications and (S)AEs;
– six months postoperatively: local physical
examination with VAS, FAOS, FAAM, SF-36, EQ-
5D, TiC, X-ray (best view for analyzing the fracture),
resumption of sports and work, complications and
(S)AEs;
– one year postoperatively: local physical examination
with VAS, FAOS, FAAM, SF-36. EQ-5D, TiC, X-ray
(best view for analyzing the fracture), resumption of
sports and work, complications and (S)AEs
If union is not yet achieved after 14 weeks, patients
are seen as determined by the responsible physician. At
every subsequent visit at least an X-ray is made to be
able to evaluate the status of the fracture (primary
outcome).
Withdrawal of subjects
Subjects can leave the study at any time for any reason if
they wish to do so, without any consequences. The in-
vestigator can decide to withdraw a subject from the
study for urgent medical reasons. Subjects will not be re-
placed after withdrawal. Data of a withdrawn subject will
be used, but we will delineate from which visit (time
point) data is incomplete and (if known) why the subject
is sequestered. To investigate why subjects are with-
drawn, they will be contacted by telephone and/or letter
to assure the reason for their withdrawal and to ask
them to come in for an optional final visit.
Sample size
The sample size calculation was performed based on
time to radiological union. Significance level was set at
p < 0,05. In recent studies, the mean time to union was
12 weeks [11, 12]. We argue that reducing this with
2 weeks would be clinically relevant: Group 1 (without
cB + cBMA) has a mean of 12 weeks, group 2 (with cB +
cBMA) a mean of 10 weeks. As the standard deviation is
difficult to determine, we estimated SD with use of the
method described by Walter and Yao [42], which re-
sulted in an SD of 1.88 weeks.
To achieve a power of 90 % (with an effect size of
1,06) we need a number of 20 patients in each group.Taking into account a possible dropout-rate of max-
imally 20 %, we need 25 patients in each randomization
arm. This calculation will be validated and altered as
needed after the interim analysis according to O’Brien
[43] and performed when 10 patients enrolled in each
arm (40 %) have reached the 14 weeks’ time point. This
analysis reduces the significance of the final comparison
of the primary outcome to p = 0.049. When a difference
of ≥3 weeks between the means of the primary outcome
among the groups is detected (SD 1.88) at the interim
analysis; a significance is already found (p = 0.003).
Statistical methods
An online, quality-assured, digital database will be
created containing the data. The analyses will be per-
formed with SPSS statistical package (version 17.0; SPSS,
Chicago, Illinois). Patient’s demographics, gender, age,
height, weight, affected side will be described for both
treatment groups and safety will be assessed by identify-
ing and summarizing complications and other clinically
relevant adverse events collected throughout the study.
Continuous data will be presented as the mean (and
standard deviation) if normally distributed (according to
Fischers exact or eyeball test); otherwise, the medians (with
range) will be reported. Dichotomous data will be presented
as frequencies (with accompanying percentages).
To check the distribution of the baseline characteris-
tics, the treatment groups will be compared using Stu-
dent’s t-tests or chi-square tests, depending of the type
of outcome measure.
The primary endpoint – number of weeks until patients
achieved radiological union postoperatively – will be ana-
lyzed using a student’s t-test or equivalent; this parameter
will be used for clinical union as well. A chi-square test
will be used to analyze union rate at each time point, and
a student’s t-test will be used to determine statistical dif-
ferences in time to return to work and/or sport. Patient-
reported outcome measures will be analyzed using a stu-
dent’s t-test or repeated measures ANOVA.
Risk factors for the development of healing problems
(such as smoking behavior, BMI, and age) will first be iden-
tified using univariate analysis (t-tests, chi-squared tests).
In case of significance (significance level will be set at 0.1),
the risk factors will be entered in a multivariate logistic re-
gression model. The cBMA analysis will be reported as ab-
solute cell count and in % of cell types. Data on the bone
biopsies of the stress fractures will be descriptive.
A comprehensive, updated sample size justification
and statistical plan will be created together with an in-
terim report after the interim analysis.
Quality assurance
A clinical research associate from our Clinical Research
Unit will monitor the trial. Monitoring will consist of
Weel et al. BMC Musculoskeletal Disorders  (2015) 16:211 Page 7 of 8100 % check informed consent procedure, registration of
adverse events, completeness of the trial master file, and
verification of source data (primary outcome in a 10 %
sample).
Public disclosure and publication policy
This trial has been registered in the Netherlands Trial
Register (NTR4377), and about to start including pa-
tients and data collection. Publication will be in accord-
ance with the basic principles of the International
Committee of Medical Journal Editors on publication
policy [44]. The writing committee will consist of the
following people: H. Weel, L. Blankevoort and G.M.M.J.
Kerkhoffs. All other individuals who made and will make
substantial scientific contributions to the conduction of
the trial and to the final manuscript will be listed as an
author. Individuals who make substantial contributions
to the conduction of the trial will be acknowledged at
the discretion of the writing committee.
Discussion
In this paper the rationale for the study and the protocol
for conducting a double-blind, randomized, controlled trial
on the effectiveness of adding cB + cBMA to the operative
treatment of MT-V stress fractures are described.
Time to union is the primary outcome measure. This is
not easy to be objectively determined, therefore 2 experi-
enced, blinded observers (experienced skeletal radiologist
and orthopaedic surgeon) will assess this outcome.
This trial will not only contribute to the knowledge of
effectiveness of bone marrow cells in stress fractures.
Because the consistence and consistency of the cBMA
product is also measured, we will learn more about which
working mechanisms and osteoprogenitor support of the
bone marrow cells are presented in fracture healing. Given
the relatively minimally invasive intervention of aspirating
autologous bone marrow, its simple and fast concentra-
tion into cBMA and the easy way of adding it locally, it
has high potential to provide a safe and effective add-
itional treatment option for stress fractures and other frac-
tures predisposed for delayed- or non-union.
Additionally, the results of this study could also help in
a better understanding of the healing pathways of stress
fractures in general. Theretofore, a biopsy is taken from
all fractures to be histologically analysed, because the heal-
ing pathways in stress fractures are still underexposed.
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